Literature DB >> 3146348

Effectors of the activation of human [Glu1]plasminogen by human tissue plasminogen activator.

T Urano1, V Sator de Serrano, P J Gaffney, F J Castellino.   

Abstract

The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen). Chloride functions as a result of its binding to [Glu1]Pg, with a Ki of approximately 9.0 mM, thereby rendering [Glu1]Pg a less effective substrate for two-chain rec-t-PA. EACA stimulates the activation in Cl-(-)containing solutions, with a Ka of approximately 4.0 mM, primarily by reversal of the Cl-(-)inhibitory effect. Fibrinogen appears to exert its stimulatory properties mainly through effects on the enzyme, two-chain rec-t-PA, with a Ka of approximately 3.7 microM in activation systems containing physiological levels of Cl-. Analysis of the results of this paper reveals that normal plasma components, Cl- and fibrinogen, exert major regulatory roles on the ability of [Glu1]Pg to be activated by two-chain rec-t-PA, in in vitro systems. The presence of Cl- inhibits the stimulation of [Glu1]Pg activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146348     DOI: 10.1021/bi00417a049

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Skizzle is a novel plasminogen- and plasmin-binding protein from Streptococcus agalactiae that targets proteins of human fibrinolysis to promote plasmin generation.

Authors:  Karen G Wiles; Peter Panizzi; Heather K Kroh; Paul E Bock
Journal:  J Biol Chem       Date:  2010-04-30       Impact factor: 5.157

Review 2.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

Review 3.  New insights into the role of Plg-RKT in macrophage recruitment.

Authors:  Lindsey A Miles; Shahrzad Lighvani; Nagyung Baik; Caitlin M Parmer; Sophia Khaldoyanidi; Barbara M Mueller; Robert J Parmer
Journal:  Int Rev Cell Mol Biol       Date:  2014       Impact factor: 6.813

Review 4.  Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-12-08       Impact factor: 5.922

5.  Influence of various structural domains of fibrinogen and fibrin on the potentiation of plasminogen activation by recombinant tissue plasminogen activator.

Authors:  V S de Serrano; T Urano; P J Gaffney; F J Castellino
Journal:  J Protein Chem       Date:  1989-02

6.  Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.

Authors:  S Urano; A R Metzger; F J Castellino
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

Review 7.  Tissue plasminogen activator for thrombolytic therapy: expectation versus reality.

Authors:  P J Gaffney
Journal:  J R Soc Med       Date:  1992-11       Impact factor: 18.000

8.  Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain.

Authors:  Yogesh Kumar; Kanagasabai Vadivel; Amy E Schmidt; Godwin I Ogueli; Sathya M Ponnuraj; Nalaka Rannulu; Joseph A Loo; Madhu S Bajaj; S Paul Bajaj
Journal:  Biochemistry       Date:  2014-01-13       Impact factor: 3.162

9.  Tranexamic acid alters the immunophenotype of phagocytes after lower limb surgery.

Authors:  Dominik F Draxler; Gryselda Hanafi; Saffanah Zahra; Fiona McCutcheon; Heidi Ho; Charithani B Keragala; Zikou Liu; David Daly; Thomas Painter; Sophia Wallace; Magdalena Plebanski; Paul S Myles; Robert L Medcalf
Journal:  Thromb J       Date:  2022-04-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.